{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:06:41Z","timestamp":1784581601335,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hoc.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:41:00Z","timestamp":1781901660000},"page":"429-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathology of Liver and Biliary Neoplasms"],"prefix":"10.1016","volume":"40","author":[{"given":"Deepinder","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2026.05.001_bib1","first-page":"427","article-title":"Anatomy of the liver","volume":"38","author":"Mahadevan","year":"2020","journal-title":"Surg Oxf"},{"key":"10.1016\/j.hoc.2026.05.001_bib2","series-title":"Histology for pathologists","first-page":"692","article-title":"Liver","author":"Mills","year":"2020"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.001_bib5","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/path.5243","article-title":"Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma","volume":"248","author":"Joseph","year":"2019","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4254\/wjh.v13.i4.393","article-title":"Pathologic and molecular features of hepatocellular carcinoma: an update","volume":"13","author":"Vij","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.001_bib8","first-page":"1","volume":"314","author":"Jiaquan","year":"2018"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gtc.2023.11.005","article-title":"Hepatic precancerous lesions and early hepatocellular carcinoma","volume":"53","author":"Wen","year":"2024","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.001_bib10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.001_bib11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.001_bib12","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/hep.27372","article-title":"Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis","volume":"60","author":"Nault","year":"2014","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.001_bib13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2017.08.013","article-title":"Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma","volume":"67","author":"Torrecilla","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.001_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.03.005","article-title":"Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation","volume":"25","author":"Pilati","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2026.05.001_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104869","article-title":"Targeting hepatocellular carcinoma: molecular mechanisms and clinical studies","volume":"213","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.001_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21037\/hbsn-22-135","article-title":"Genomic alterations in hepatocellular carcinoma and their clinical application to genomic medicine","volume":"11","author":"Imamura","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.17998\/jlc.20.1.17","article-title":"Histopathological variants of hepatocellular carcinomas: an update according to the 5th Edition of the WHO classification of digestive system tumors","volume":"20","author":"Kim","year":"2020","journal-title":"J Liver Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.001_bib20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.humpath.2015.07.018","article-title":"Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study","volume":"46","author":"Yeh","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2020.12.009","article-title":"Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes","volume":"112","author":"Torbenson","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/JHC.S364742","article-title":"Macrotrabecular-massive hepatocellular carcinoma: what should we know?","volume":"9","author":"Li","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.hoc.2026.05.001_bib23","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.4103\/IJPM.IJPM_751_20","article-title":"An update on subtypes of hepatocellular carcinoma: from morphology to molecular","volume":"64","author":"Vyas","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.hoc.2026.05.001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154655","article-title":"Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: a state of art review of the current literature","volume":"248","author":"Alshareefy","year":"2023","journal-title":"Pathol Res Pract"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/10668969241291882","article-title":"Clinicopathological characteristics of neutrophil-rich hepatocellular carcinoma: an uncommon subtype of primary liver cancer","volume":"33","author":"Vij","year":"2025","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/liv.15865","article-title":"Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures","volume":"44","author":"Ahn","year":"2024","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.hoc.2026.05.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112056","article-title":"Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection","volume":"187","author":"Glushko","year":"2025","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.hoc.2026.05.001_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.857140","article-title":"Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma","volume":"9","author":"Chung","year":"2022","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.001_bib30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cells9030688","article-title":"New and emerging systemic therapeutic options for advanced cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.hoc.2026.05.001_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.anndiagpath.2018.10.005","article-title":"Update on the pathology of liver neoplasms","volume":"38","author":"Matsukuma","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.001_bib32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/modpathol.2008.85","article-title":"Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum","volume":"21","author":"Shafizadeh","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105794","article-title":"Role of genomic analysis in the classification of well-differentiated hepatocellular lesions","volume":"158","author":"Akarca","year":"2025","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/path.825","article-title":"Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization","volume":"193","author":"Wilkens","year":"2001","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.001_bib35","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/cancers13081830","article-title":"\u03b2-Catenin activation in hepatocellular cancer: implications in biology and therapy","volume":"13","author":"Krutsenko","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.hoc.2026.05.001_bib36","article-title":"Exploring the impact of the \u03b2-catenin mutations in hepatocellular carcinoma: an in-depth review","volume":"31","author":"Idrissi","year":"2024","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.001_bib37","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/cancers13092160","article-title":"Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma","volume":"13","author":"Jang","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.14858","article-title":"Genetic and epigenetic analysis of hepatocellular adenomas with atypical morphological features","volume":"82","author":"Haefliger","year":"2023","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.humpath.2012.07.019","article-title":"Atypical hepatocellular adenoma-like neoplasms with \u03b2-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas","volume":"44","author":"Evason","year":"2013","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.001_bib40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.14309\/ajg.0000000000002857","article-title":"ACG clinical guideline: focal liver lesions","volume":"119","author":"Frenette","year":"2024","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.001_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100211","article-title":"Borderline hepatocellular adenomas: a practical diagnostic approach based on pathologic and molecular features","volume":"36","author":"Pot\u00e9","year":"2023","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.001_bib42","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/cancers13122871","article-title":"Histological heterogeneity of primary liver cancers: clinical relevance, diagnostic pitfalls and the pathologist\u2019s role","volume":"13","author":"Komuta","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5858\/arpa.2020-0725-OA","article-title":"HNF-1\u03b2 is a more sensitive and specific marker than C-reactive protein for identifying biliary differentiation in primary hepatic carcinomas","volume":"146","author":"Patil","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcp\/aqz032","article-title":"Albumin in-situ hybridization can be positive in adenocarcinomas and other tumors from diverse sites","volume":"152","author":"Nasir","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ajcp\/aqw096","article-title":"Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms: a potential diagnostic pitfall","volume":"146","author":"Askan","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.001_bib46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/PAS.0000000000002116","article-title":"Genomic analysis in the categorization of poorly-differentiated primary liver carcinomas","volume":"47","author":"Kikuchi","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.001_bib47","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/00000478-200310000-00002","article-title":"Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases","volume":"27","author":"Terracciano","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.humpath.2022.06.011","article-title":"Hepatoid tumors of the gastrointestinal\/pancreatobiliary district: morphology, immunohistochemistry, and molecular profiles","volume":"132","author":"Mattiolo","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib49","article-title":"Hepatoid adenocarcinoma of the stomach: current perspectives and new developments","volume":"11","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2026.05.001_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.03.006","article-title":"Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist","volume":"88","author":"Tsuruta","year":"2019","journal-title":"Hum Pathol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.001_bib51","doi-asserted-by":"crossref","first-page":"18241","DOI":"10.1007\/s00432-023-05488-2","article-title":"A case report of two instances of colorectal hepatoid adenocarcinoma, accompanied by a comprehensive literature review","volume":"149","author":"Zhang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02237252","article-title":"Hepatoid adenocarcinoma of the rectum arising in ulcerative colitis: report of a case","volume":"43","author":"Lattes","year":"2000","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.001_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","article-title":"Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification","volume":"31","author":"Xue","year":"2020","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib54","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/PAS.0000000000000585","article-title":"BSEP and MDR3: useful immunohistochemical markers to discriminate hepatocellular carcinomas from intrahepatic cholangiocarcinomas and hepatoid carcinomas","volume":"40","author":"Fujikura","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib55","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2024.42.3_suppl.394","article-title":"Molecular profiling of hepatoid adenocarcinoma and adenocarcinoma with enteroblastic differentiation","volume":"42","author":"Matsumoto","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/jclinpath-2020-206574","article-title":"Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation","volume":"74","author":"Tefera","year":"2021","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2019.12.006","article-title":"BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA","volume":"72","author":"Hirsch","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.001_bib58","doi-asserted-by":"crossref","first-page":"e16330","DOI":"10.1200\/JCO.2025.43.16_suppl.e16330","article-title":"Exploring survival outcomes in sarcomatoid hepatocellular carcinomas in the era of immunotherapy","volume":"43","author":"Abdelhakeem","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.001_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2021.09.009","article-title":"Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification","volume":"119","author":"Torbenson","year":"2022","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.001_bib60","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3390\/biomedicines11092582","article-title":"Advances in histological and molecular classification of hepatocellular carcinoma","volume":"11","author":"Choi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.hoc.2026.05.001_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.humpath.2022.06.001","article-title":"Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities","volume":"132","author":"Zen","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2026.05.001_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.humpath.2024.01.011","article-title":"Enteroblastic cholangiocarcinoma: an uncommon, underrecognized subtype of bile duct cancer","volume":"144","author":"Chun","year":"2024","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/PAS.0000000000002365","article-title":"Cholangioblastic cholangiocarcinoma (NIPBL::NACC1 Cholangiocarcinoma): expanded morphologic spectrum and further genetic characterization","volume":"49","author":"Argani","year":"2025","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib64","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1038\/s41467-025-60999-5","article-title":"Epstein Barr virus antibody and cancer risk in two prospective cohorts in Southern China","volume":"16","author":"Ji","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.001_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.001_bib66","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P","article-title":"Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases","volume":"73","author":"Higuchi","year":"1994","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3748\/wjg.v2.i2.79","article-title":"Histopathological study of hepatocellular carcinoma after transcatheter hepatic arterial embolization","volume":"2","author":"Ji","year":"1996","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hoc.2026.05.001_bib68","first-page":"677","article-title":"Histological aspects of post-TACE hepatocellular carcinoma","volume":"53","author":"Cotoi","year":"2012","journal-title":"Rom J Morphol Embryol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib69","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10620-007-9986-y","article-title":"Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients","volume":"53","author":"Morisco","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.001_bib70","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/hep.30406","article-title":"Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers","volume":"70","author":"Bale","year":"2019","journal-title":"Hepatol Baltim Md"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.001_bib71","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/PAS.0000000000001223","article-title":"90Y-TheraSpheres: the new look of Yttrium-90","volume":"43","author":"Arnold","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3349\/ymj.1991.32.2.147","article-title":"Histological studies of surgically resected hepatocellular carcinoma following combined radiotherapy and hyperthermia","volume":"32","author":"Seong","year":"1991","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib74","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3350\/cmh.2016.0070","article-title":"Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.001_bib75","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41379-020-00679-5","article-title":"Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy","volume":"34","author":"Simoes","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.001_bib76","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.001_bib77","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.001_bib78","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/PAS.0000000000002359","article-title":"Histopathologic grading of residual tumor predicts survival of intrahepatic cholangiocarcinoma patients treated with neoadjuvant therapy: major pathologic response and its clinical significance","volume":"49","author":"Wu","year":"2025","journal-title":"Am J Surg Pathol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:29:55Z","timestamp":1784579395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0889858826000419"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathology of Liver and Biliary Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}